GSK plc (GSK)'s subsidiary ViiV Healthcare, Thursday announced the completion of negotiations with the pan-Canadian Pharmaceutical Alliance or pCPA for APRETUDE for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in at-risk individuals who are HIV-1 negative.
Following this, the company will work with provincial and territorial governments and other stakeholders to make APRETUDE available through public drug plans.
Currently, GSK's stock is trading at $36.33, up 0.55 percent on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Health News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.